

## Magneto Thrombectomy Solutions ABSTRACT for Company Presentations

### Questions for categories: **Medical Devices**

- **Investment Rational:**

Magneto is developing innovative thrombectomy solutions, focusing on the treatment of Pulmonary Embolism (PE). The eRetrieve™ enables faster clot retrieval, using a smaller profile and presumably associated with fewer complications, compared with the competition. Magneto has a strong management team with extensive experience in medical device technologies; Our team has the ability to reach company's milestones in an efficient manner.
- **Business Strategy**

Magneto's eRetrieve™ System can be used as a stand-alone system to remove blood clots in PE. Once approved by the FDA, the target price is around \$10,000 per procedure.
- **Core Technology**

The technology is based on the electric properties of blood clots and uses electric fields to create an attraction with the target clots. Competing mechanical thrombectomy devices use meshes to drag-out clots, or aspiration catheters to aspirate them. Attraction vs. dragging enables eRetrieve™ to remove clots where other techniques have failed (small/distal vessels, fibrin-clots).
- **Product Profile/Pipeline**

Achieved promising results in its FIH study, using eRetrieve™ for PE. The revolutionary treatment removes all clot types and is considered an innovative solution for PE. PE is a rapidly growing market, enhanced by the hospitals' Pulmonary Embolism Response Team (PERT). eRetrieve™ offers a safer and more effective solution for ~200,000 patients, compared with alternatives. Potential US Market: ~\$2.0B (US).
- **What's Next?**

Magneto is focusing on its US IDE study for FDA approval and received positive feedback during initial discussions with the FDA. The company is currently seeking for investment to finance FDA's approval of its PE product.
- **Key Markets:**

In which territories are your expertise and services relevant?